{"denoms":[{"counts":[{"groupId":"BG000","value":"33"}],"units":"Participants"}],"groups":[{"description":"Fludarabine 25 mg/m\\^2 intravenous (IV) daily for 5 days prior to allogeneic peripheral blood progenitor cell (PBPC) , Melphalan 70 mg/m\\^2 IV daily for 2 days prior to IV Allogeneic Transplant following Fludarabine \\& Melphalan. Thymoglobulin 2 mg/kg/day IV on days -3, -2 \\& -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.","id":"BG000","title":"Fludarabine + Melphalan With PBPC"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"20","upperLimit":"67","value":"55"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"18"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"15"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"33"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}